DANIEL SMITH: Open Payments
NPI 1528562865 · FARMINGTON HILLS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$872 in 33 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $16 · 2025 $872
Food & beverage: $872
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $207 |
| Janssen Pharmaceuticals, Inc | 10 | $178 |
| Neurocrine BioSciences, Inc. | 1 | $127 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Lundbeck LLC | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
Products named: VRAYLAR, INVEGA SUSTENNA, INGREZZA, Auvelity, REXULTI, CAPLYTA, UZEDY, ZEPBOUND.
Industry payments across MI — which companies pay providers there.
